Download Free Medical Thyroid Cancer PowerPoint Presentation

Thyroid Cancer PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation on cancer titled "Thyroid Cancer" talks about thyroid cancer, and, its anatomy and blood supply, its epidemiology, its causes and risk factors, its classification, its clinical presentation, its diagnosis, and its management.

Tags : Cancer, Thyroid Cancer, anatomy, blood supply, epidemiology, causes, risk factors, classification, clinical presentation, diagnosis, management, Evaluation, Thyroid profile, Serum Thyroglobulin, Serum Calcitonin, Thyroid scan, malignant, Serum, Diagnosis, FNA Cytology, Thyroid Surgeries, Ipsilateral lobectomy, Subtotal Thyroidectomy, Near-total Thyroidectomy, Total Thyroidectomy, Papillary Carcinoma

Published on : May 03, 2021 | Views : 4012 | Downloads : 44

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Thyroid Cancer Dr. Awad Alqahtani Md,MSc.FRCSC(G.Surgery)FRCSC(Surgical Oncology) Laparoscopic and Bariatric Surgery
Slide 2-

Outlines Anatomy and Blood Supply Epidemiology Causes and Risk Factors Classification Clinical Presentation Diagnosis Management
Slide 3-

ppt slide no 3 content not found
Slide 4-

ppt slide no 4 content not found
Slide 5-

ppt slide no 5 content not found
Slide 6-

Epidemiology Commonest endocrine malignancy 1% of all malignancies 0.5-1 per 100000 Good prognosis Extent of treatment is hotly debated No randomized trials Annual Incidence is 3.7 per 100,000 Sex Ratio is 3:1 (Female:Male) Can occur at any age group
Slide 7-

Causes and Risk Factors Genetics: Abnormal RET oncogene may cause MTC. MEN 2A, 2B Syndrome. Family History: Hx of goiters increase risk for Papillary Ca. Gardner’s Syndrome and FAP increase risk for Papillary Ca. Radiation Exposure: Radiation therapy to Head or Neck. Exposure to Radioactive Iodine during childhood, or other radioactive substances (Chernobyl) ↑ risk for particularly Papillary carcinoma.
Slide 8-

Causes and Risk Factors Chronic Iodine deficiency ↑ risk for Follicular carcinoma. Gender: Female > Males. Age: More common at young adults. MTC usually diagnosed after 60. Race: White race > Black race.
Slide 9-

Thyroid Neoplasm Benign Malignant Secondary Primary Follicular Cells Parafollicular Cells Lymphoid Cells Lymphoma Medullary Differentiated Undifferentiated Anaplastic Follicular Papillary Hurthle Cell
Slide 10-

Presentation Solitary or Multiple thyroid nodules Neck Nodes Hoarse voice of recent onset Mediastinal adenopathy Bone or lung metastasis
Slide 11-

Important History Radiation to neck / chest MEN syndrome Family history Diarrhoea Adrenal tumour Recent change in a pre-existing goitre Size change/nodularity Vocal cord palsy
Slide 12-

Evaluation Thyroid profile Serum Thyroglobulin Serum Calcitonin Thyroid scan Hot/warm/cold nodule 20% malignant Serum Ca++
Slide 13-

Diagnosis Laboratory: TSH T3, T4 Serum Thyroglobulin Serum Thyroid Antibodies FNA Imaging U/S C.T MRI Scintigraphy
Slide 14-

Laboratory Most patients are Euthyroid. Hyperfunctioning nodule  1% chance of malignancy. Serum Tg cannot differentiate between benign and Malignant nodules Tg is used for: F/U after total thyroidectomy Serial F/U for non-operative treatment Serum Calcitonin  patients with MTC, or with family hx of MTC (MEN2)
Slide 15-

FNA Cytology Single most important test. U/S guidance improve the sensitivity. Accuracy ranges from 70 – 95%. Nodules FNAC cannot differentiate between Benign and Malignant Follicular Neoplasia
Slide 16-

ppt slide no 16 content not found
Slide 17-

Imaging U/S is the investigation of choice. C.T  Regional and distant metastases MRI  Limited role in the diagnosis Useful in detecting cervical LN metastases Scintigraphy (I-123) Characterizing funtioning nodules Staging of follicular and papillary Ca
Slide 18-

Prognostic Indicators AGES score: Age Hisological Grade Extrathyroidal invasion Metastasis MACIS score (post-operative): Distant Metastasis Age Completeness of original surgical resection Extrathyroidal Invasion Size of original lesion
Slide 19-

ppt slide no 19 content not found
Slide 20-

ppt slide no 20 content not found
Slide 21-

Management Medical Radioactive Iodine ablation therapy. Chemotherapy (Adriamycin, Cisplatin). Post-operative Thyroid hormone. Replacement therapy. Suppression of TSH release. (↓ recurrence) Surgical Treatment of choice. Extent of resection is still controversial.
Slide 22-

Thyroid Surgeries Relates to the management of contralateral lobe. Types Ipsilateral lobectomy Subtotal Thyroidectomy Near-total Thyroidectomy Total Thyroidectomy
Slide 23-

Papillary Carcinoma Most common Thyroid carcinoma (80%) Related to radiation exposure in I-sufficient areas. Female:male ratio is 2:1 Mean age of presentation is 30 to 40 yrs. Slow growing painless mass. Euthyroid-status. LN metastases is common, may be the presenting symptom (Lateral Aberrant Thyroid). Distant metastases is uncommon at initial presentation. Develop in 20% of cases. (Lungs, liver, bones,brain)
Slide 24-

Papillary Carcinoma FNA biopsy is diagnostic. Treatment Ipsilateral Lobectomy + Isthmusectomy (No LN metastasis) Near-total or Total Thyroidectomy + Modified-radical or Functional neck dissection (+ve LN metastasis). Prophylactic LN dissection is unnecessary.
Slide 25-

Follicular Carcinoma Account for 10% of all thyroid cancers. More common in I-deficient areas. Female:male ratio is 3:1 Mean age at presentation is 50 yrs. Solitary thyroid nodule, rapid increase in size and long-standing goiter. Cervical LN metastasis is uncommon at presentation (5%), distant metastasis may be present. Hyperfunctioning < 1%. (S&S of Thyrotoxicosis)
Slide 26-

Follicular Carcinoma FNA biopsy cannot differentiate between benign and malignant follicular tumors. Pre-operative diagnosis of malignancy is difficult unless there is distant metastasis. Large follicular tumor > 4 cm in old individual  CA. Treatment: Thyroid Lobectomy (at least 80% are benign adenomas) Total-Thyroidectomy in older individual with tumor > 4cm (50% chance of malignancy). Prophylactic nodal dissection is unnecessary.
Slide 27-

ppt slide no 27 content not found
Slide 28-

Post-operative Management Thyroid hormone Replacement therapy Suppression of TSH release At 0.1 μU/L in Low-risk group < 0.1 μU/L in High-risk group Thyroglobulin measurement At 6-months interval then annually when disease-free < 2ng/mL in total or near-total + Hormones < 5ng/mL in hypothyroid patients. Level > 2ng/mL = Recurrence/Persistent thyroid tissue
Slide 29-

Post-operative Management Radioiodine Therapy: Controversial (No prospective RCTs). Long-term cohort studies by Mazzaferri and Jhiang and DeGroot: Small improvement in survival rate and less recurrence when RAI is used, even with Low-risk group. RAI is less sensitive than Tg in detecting metastatic disease. I-131 detect and treat 75% of metastatic differentiated thyroid tumors.
Slide 30-

Medullary Carcinoma 5% of all thyroid malignancies. Arise from Parafollicular cells, concentrated in superolateral aspect of thyroid lobes. Most cases are sporadic, 25% are inherited (Germline mutation in RET oncogene). Female:Male ratio is 1.5:1 Most patients present between 50 and 60 yrs. Neck mass + palpable cervical LN (15-20%). Local pain or aching is common.
Slide 31-

Medullary Carcinoma MTC secrets a range of compounds: Calcitonin, CEA, CGRP, PG A2 and F2α, Seritonin. May develop flushing and diarrhoea, Cushing’s syndome (ectopic ACTH). Diagnosis Hx and P/E (Family hx of similar tumors). ↑ Serum Calcitonin, ↑ CEA FNAC Screen patient for: RET point mutation. Coexisting Pheochromocytoma (24-hour urinary level of VMA, catecholamine, metanephrine). Hyperparathyroidism (Serum calcium).
Slide 32-

ppt slide no 32 content not found
Slide 33-

Medullary Carcinoma Treatment: > 50% are bilateral, ↑ Multicentricity. Total Thyroidectomy + : Bilateral central node dissection as routine (No LN involvement) Bilateral Modified-Radical Neck dissection (palpable LN) Ipsilateral Prophylactic nodal dissection in tumor size > 1.5cm. External Beam radiation for unresectable residual or recurrent tumor. No effective Chemotherapy.
Slide 34-

Medullary Carcinoma Prophylactic Thyroidectomy in RET mutation detection Before age of 6 yrs for MEN2A Before age of 1 yr for MEN2B
Slide 35-

Anaplastic Carcinoma 1% of all thyroid malignancies. Women > Men. Majority present at 7th - 8th decade of life. Long-standing neck mass, rapidly enlarging in size. May be painful, with dyphonia, dyspnea, dysphagia. LN are usually involved at presentation. ± Distant metastasis.
Slide 36-

Anaplastic Carcinoma FNAC is diagnostic. Treatment: Most aggressive thyroid tumor. Total Thyroidectomy if resectable. Adjuvant Chemotherapy + Radiotherapy slightly improve long-term survival.
Slide 37-

Other Types Thyroid Lymphoma: 1% of all Thyroid Ca. Most are Non-Hodgkin B-cell Lymphoma. Underlying chronic lymphocytic thyroiditis. FNAC is diagnostic. Combined Chemotherapy (CHOP) + Radiotherapy. Hurthle-Cell Carcinoma: 3% of all Thyroid Ca. Subtype of Follicular Ca. More multicenteric and bilateral (30%). FNAC is not conclusive. Lobectomy + isthmusectomy (unilateral) Total Thyroidectomy (bilateral)
Slide 38-

Prognosis